Healthcare cost and utilization for chimeric antigen receptor ( CAR ) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis
Cancer Reports · 2024
DOI: 10.1002/cnr2.1980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Alex Hoover und 7 weiteren Autor:innen. Beteiligte Einrichtung: Optum Labs Visiting Fellow, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
B‐lineage acute lymphoblastic leukemia (B‐ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial burden experienced by patients and society requires evaluation.
Aims
This study aims to assess the utilization and cost of care for chimeric antigen receptor T‐cell (CAR‐T) therapy for pediatric ALL patients with commercial insurance coverage in the United States. Methods and Results Using de‐identified commercial insurance data from the OptumLabs® Data Warehouse, a cohort of 37 patients, aged 1‐25 years, with B‐ALL treated with CAR‐T therapy between Oct 2016 and Dec 2021 in the United States was identified. Cost was evaluated for a 90 day period encompassing CAR‐T infusion and by administration and complication characteristics. Among the 37 identified B‐ALL patients that received a CAR‐T product infusion, 14 patients were female, median age at administration was 13 years. The median 90‐day total cost was $620,500 (Mean: $589,108). Inpatient cost accounted for approximately 71% of the total cost with an average of 28 inpatient days per patient. Although inpatient cost was slightly higher in the older age group (aged 10‐25 years) and in patients with a code for cytokine release syndrome (CRS), these differences were not statistically significant.
Conclusion
This real‐world cost analysis shows for the first time the encompassing cost of CAR‐T therapy for pediatric B‐ALL patients in the US with commercial insurance. This study provides a valuable benchmark that can be used to analyze the financial implications of CAR‐T therapy for pediatric B‐ALL therapy on health systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Optum Labs Visiting Fellow, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Pediatrics, Children's Minnesota, Minneapolis, Minnesota, USA.
- Graduate College, Division of Physical Therapy, St. Catherine University, St. Paul, Minnesota, USA.
ORCID-Profile: Alex Hoover, Lynn Tanner, Yoav H Messinger
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
- Children's Cancer Research Fund
Zitieren
APA
Hoover, A., Reimche, P., Watson, D., Tanner, L., Gilchrist, L., Finch, M., Messinger, Y. H., & Turcotte, L. M. (2024). Healthcare cost and utilization for chimeric antigen receptor ( CAR ) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis. Cancer Reports. https://doi.org/10.1002/cnr2.1980
Vancouver
Hoover A, Reimche P, Watson D, Tanner L, Gilchrist L, Finch M, et al. Healthcare cost and utilization for chimeric antigen receptor ( CAR ) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis. Cancer Reports. 2024. doi:10.1002/cnr2.1980
BibTeX
@article{Hoover2024,
author = {Hoover, Alex and Reimche, Paige and Watson, Dave and Tanner, Lynn and Gilchrist, Laura and Finch, Mike and Messinger, Yoav H and Turcotte, Lucie M},
title = {Healthcare cost and utilization for chimeric antigen receptor ( CAR ) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1980}
}
EUVIMED